Belinostat (PXD101)

Catalog #: 27608-2
Size: 50 mg
$295
MW: 318.4 Da
CAS Registry #: 414864-00-9
Formula: C15H14N2O4S
Target: HDAC
Background:
Belinostat has been found to significantly increase the acetylation of histones H3 and H4 and exerts cytotoxicity in a wide range of tumor cell lines.
Description:
Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.
Synonym(s):
PXD-101, PXD 101, PX105684, PX-105684, (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Purity:

≥98% by HPLC

Biological Activity:
Belinostat (also known as PXD101) is a novel and potent hydroxamate-type inhibitor of histone deacetylase (HDAC) that inhibits the activity of HDAC in Hela cell extracts with IC50 value of 27 nM. In the treatment of urothelial carcinoma cell lines, belinostat dose-dependently inhibits proliferation in 5637, T24, J82 and RT4 cells with IC50 values of 1.0 µM, 3.5 µM, 6.0 µM and 10 µM respectively; while, in prostate cancer cell lines, it inhibits cancer cell growth with IC50 values ranging from 0.5 to 2.5 µM.
Solubility:
Soluble in DMSO
Storage / Stability:

Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.

Reference(s):
1. Buckley,MT, et al. J. Transl. Med. 2007; 5:49.
2. Gravina, GL et al. Int. J. Oncol. 40: 711-720, 2012.
3. Plumb JA, et al. Mol Cancer Ther. 2003 Aug;2(8):721-8.
Scientific Category:
Deacetylase Inhibitor
Product Type:
Inhibitor
Data shown is lot-specific. Contact us for specific information on other lots.

Quality Assurance